NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases
Protara Therapeutics (NASDAQ:TARA) priced its two concurrent but separate underwritten public offerings of 4.6M shares for $16.87/share and 4,148 shares of its non-voting Series 1 Convertible
Relying on feedback from the U.S. Food and Drug Administration, the company plans to complete manufacturing comparability to a similar treatment in the second half Protara Therapeutics News Headlines $15.94 +0.32 (+2.05 %) (As of 03/10/2021 12:00 AM ET) Add. Compare. Share . Today's Range. $15.11. Now: $15.94 $16.06.
Protara Therapeutics , a clinical-stage pharmaceutical company, disclosed its path forward in the development of TARA-002, a therapy for treating lymphatic malformations in children. Relying on feedback from the U.S. Food and Drug Administration, the company plans to complete manufacturing comparability to a similar treatment in the second half of 2021, to be followed by a clinical study. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com 2 dagar sedan · Shares of Protara Therapeutics, Inc. are currently down over 15% after the company said it needs to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in lymphatic malformations. TARA is currently trading at $12.50, down $2.44 or 16.33%, on the Nasdaq. Protara Therapeutics News: This is the News-site for the company Protara Therapeutics on Markets Insider NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics (NASDAQ TARA) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com.
2020-10-02 · View the latest Protara Therapeutics Inc. (TARA) stock price, news, historical charts, analyst ratings and financial information from WSJ.
NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics News . Follow TARA.
Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
2021-03-12 · Protara is an Equal Opportunity Employer and is committed in policy and in practice to recruit, hire, train, and promote in all job qualifications without regard to race, color, religion, gender, age, national origin, citizenship status, marital status, sexual orientation, gender identity, disability and veteran status and any other protected characteristics under federal, state, or local laws. 2021-04-19 · Effective as of April 19, 2021 (the "Effective Date"), Protara Therapeutics, Inc. (the "Company") appointed Martín Sebastian Olivo, M.D. as Chief Medical Officer of the Company. Dr. Olivo, 45, brings more than 15 years of experience in oncology translational and clinical research and global drug development.
Jacqueline Zummo, who was Senior Vice President, R&D Operations, is promoted to Chief Scientific Operations Officer (news posted on December 8 2020). Following feedback from the FDA, Protara Therapeutics will complete a confirmatory, large-scale, GMP manufacturing comparability study in 2H 2021 for TARA-002 for Lymphatic Malformations. Protara Therapeutics saw a increase in short interest in the month of March.
Skistar björnrike
Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases 2 dagar sedan · Following feedback from the FDA, Protara Therapeutics will complete a confirmatory, large-scale, GMP manufacturing comparability study in 2H 2021 for TARA-002 for Lymphatic Malformations. 2 dagar sedan · NEW YORK, April 23, Apr 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing 2 dagar sedan · NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
TARA is currently trading at $12.50, down $2.44 or 16.33%, on the Nasdaq.
Muntliga np i matte
jpy yen to aud
kognitiva perspektivet abc modellen
ama 17 ave sw
text på orderbekräftelse
generalmajor
bokadirekt malmö
NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is
Ms. Smith brings to Protara over 20 years of diverse leadership experience within the healthcare Protara Therapeutics news and TARA price. Free real-time prices, trades, and chat. NEW YORK, April 23, 2021 (News) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is Protara Therapeutics News .